Determining the ED50 of Oliceridine Combined with various doses of Cyclopropofol Sedation in Elderly Patients Undergoing Gastrointestinal Endoscopy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600119596

Enrollment

Unknown

Registered

2026-02-28

Start date

2026-03-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastrointestinal endoscopy

Interventions

0.4mg group:Intravenous anesthesia with oliceridine combined with cyclopropofol. The dose of cyclopropofol is fixed at 0.4 mg/kg, and the initial dose of oliceridine is 0.02 mg/kg. Subsequently, the d

0.3mg group:Intravenous anesthesia with oliceridine combined with cyclopropofol. The dose of cyclopropofol is fixed at 0.3 mg/kg, and the initial dose of oliceridine is 0.02 mg/kg. Subsequently, the d

Eligibility

Sex/Gender

All

Age

65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Subjects clearly understood, voluntarily participated in the study and signed an informed consent form by themselves; 2. Age 65-80 years old, gender is not limited; 3. ASA grade II-III; 4. BMI 18.5kg/?=BMI<28kg/?. 5. Painless gastroenteroscopy.

Exclusion criteria

Exclusion criteria: 1. Allergy to or contraindication to cyproterone, opioids and their drug components; 2. presence of contraindications to gastroenteroscopy such as gastrointestinal obstruction; 3. severe obstructive sleep apnoea syndrome; 4. history of cranio-cerebral disease, neuropsychiatric disorders, or personal history of alcohol or drug abuse; 5. participation as a subject in a clinical trial of other drugs within the last 3 months; 6. examination time exceeding 30 minutes; 7. Abnormal liver or kidney function; 8. bradycardia, unstable angina or myocardial infarction; 9. long-term use of opioids for analgesia due to cancer pain or other chronic pain; 10. in the opinion of the investigator, should not participate in this trial.

Design outcomes

Primary

Measure	Time frame
Patient Responses During Gastroscopy;	—

Secondary

Measure	Time frame
Doses of Cyclopropofol and Oliceridine Administered to Subjects;MAP;SpO2;Adverse Events;Examination Duration;Recovery Time;Discharge Time;	—

Countries

China

Contacts

Public ContactYang Chun

The First Affiliated Hospital of Nanjing Medical University

chunyang@njmu.edu.cn+86 182 6006 2666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026